Phase 3
N=26
Emergency Treatment of Coral Snake Envenomation With Antivenom
Coral Snake Bite · Toxic Effect of Coral Snake Venom
Bottom Line
View on ClinicalTrials.gov: NCT01337245 ↗Enrolled (actual)
26
Serious AEs
11.5%
Results posted
Apr 2023
Primary outcome: Primary: Number of Participants Who Survived — 25 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Snake (Micrurus) North American immune F(ab')2 Equine (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- University of Arizona
- Primary completion
- Nov 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Survived |
25 | — |
| SECONDARY Change in Mean Venom Level From Baseline to 24 Hours |
-34.5 | — |
| SECONDARY Change in Mean Antivenom Level From Baseline to 24 Hours |
112.4 | — |
Summary
The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake.
Funding Source - FDA OOPD.
Eligibility Criteria
Inclusion Criteria
- Male or female of any age. Presenting for emergency treatment of coral snake bite.
Exclusion Criteria
- Prior use of coral snake antivenom for this envenomation. Allergy to horse serum.
Data sourced from ClinicalTrials.gov (NCT01337245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.